Trevena (NASDAQ:TRVN) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07, Morningstar.com reports. The firm had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $3.00 million.

Shares of TRVN traded up $0.02 during trading on Friday, reaching $0.66. 1,959,155 shares of the company traded hands, compared to its average volume of 5,466,274. Trevena has a twelve month low of $0.55 and a twelve month high of $3.58. The stock has a market cap of $46.48 million, a PE ratio of -0.54 and a beta of 0.61. The company has a debt-to-equity ratio of 0.28, a current ratio of 3.40 and a quick ratio of 3.40.

A number of brokerages have commented on TRVN. Zacks Investment Research raised shares of Trevena from a “hold” rating to a “buy” rating and set a $0.75 target price on the stock in a research note on Thursday. HC Wainwright downgraded shares of Trevena from a “buy” rating to a “neutral” rating and reduced their target price for the stock from $3.00 to $0.75 in a research note on Monday, November 5th. Needham & Company LLC downgraded shares of Trevena from a “buy” rating to a “hold” rating in a research note on Friday, October 12th. Jefferies Financial Group downgraded shares of Trevena from a “buy” rating to a “hold” rating and reduced their target price for the stock from $10.00 to $1.00 in a research note on Wednesday, October 10th. Finally, JMP Securities lifted their target price on shares of Trevena from $4.00 to $15.00 and gave the stock an “outperform” rating in a research note on Friday, October 12th. Four investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $5.42.

Institutional investors and hedge funds have recently made changes to their positions in the business. JPMorgan Chase & Co. increased its position in shares of Trevena by 635.7% during the first quarter. JPMorgan Chase & Co. now owns 89,228 shares of the biopharmaceutical company’s stock valued at $146,000 after acquiring an additional 77,100 shares during the last quarter. LMR Partners LLP acquired a new stake in shares of Trevena during the second quarter valued at about $207,000. Schwab Charles Investment Management Inc. increased its position in shares of Trevena by 55.0% during the first quarter. Schwab Charles Investment Management Inc. now owns 144,362 shares of the biopharmaceutical company’s stock valued at $237,000 after acquiring an additional 51,200 shares during the last quarter. Paloma Partners Management Co acquired a new stake in shares of Trevena during the second quarter valued at about $411,000. Finally, GSA Capital Partners LLP increased its position in shares of Trevena by 186.2% during the second quarter. GSA Capital Partners LLP now owns 351,847 shares of the biopharmaceutical company’s stock valued at $507,000 after acquiring an additional 228,900 shares during the last quarter. Institutional investors and hedge funds own 42.33% of the company’s stock.

WARNING: “Trevena (TRVN) Announces Earnings Results” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this news story on another website, it was copied illegally and republished in violation of U.S. and international trademark and copyright law. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2018/11/10/trevena-trvn-announces-earnings-results.html.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, develops therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions. Its product candidates include OLINVO injection, a G protein biased ligand of the µ opioid receptor that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is preferred; TRV250, a G protein biased ligand targeting the d-receptor, which is in Phase I clinical study for the treatment of migraine; and TRV734, a small molecule G protein biased ligand of the µ opioid receptor that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain, as well as TRV027 for the treatment of acute heart failure.

Featured Story: Return on Investment (ROI) Defined, Explained

Earnings History for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.